Bliss GVS Pharma Limited (BOM:506197)
India · Delayed Price · Currency is INR 709.30
+23.40 (3.41%)
At close: Sep 25, 2026
Bliss GVS Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 75,381 | 22,803 | 12,386 | 11,793 | 7,421 | 7,978 | |
Market Cap Growth | 371.45% | 84.10% | 5.03% | 58.92% | -6.98% | -21.63% |
Enterprise Value | 74,101 | 21,680 | 11,511 | 11,487 | 7,314 | 7,890 |
Last Close Price | 709.30 | 215.13 | 116.69 | 111.34 | 69.97 | 75.06 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 56.20 | 17.66 | 14.69 | 15.63 | 10.47 | 53.05 |
Forward PE | - | 6.57 | 6.57 | 6.57 | 6.57 | 6.57 |
PS Ratio | 7.50 | 2.46 | 1.53 | 1.53 | 0.99 | 1.07 |
PB Ratio | 6.12 | 1.85 | 1.13 | 1.18 | 0.81 | 0.94 |
P/TBV Ratio | 6.36 | 1.92 | 1.19 | 1.23 | 0.85 | 0.98 |
P/FCF Ratio | 92.06 | 27.85 | 41.81 | 15.83 | - | 12.98 |
P/OCF Ratio | 54.34 | 16.44 | 11.70 | 11.47 | 21.63 | 5.89 |
PEG Ratio | - | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 7.37 | 2.34 | 1.42 | 1.49 | 0.97 | 1.06 |
EV/EBITDA Ratio | 37.35 | 13.70 | 9.38 | 7.77 | 6.31 | 6.77 |
EV/EBIT Ratio | 45.07 | 16.54 | 11.78 | 9.25 | 7.42 | 7.79 |
EV/FCF Ratio | 90.49 | 26.48 | 38.85 | 15.42 | - | 12.83 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.08 | 0.10 | 0.11 | 0.13 |
Debt / EBITDA Ratio | 0.11 | 0.13 | 0.69 | 0.66 | 0.87 | 0.92 |
Debt / FCF Ratio | - | 0.27 | 2.97 | 1.34 | - | 1.78 |
Net Debt / Equity Ratio | -0.13 | -0.13 | -0.05 | -0.04 | 0.04 | -0.03 |
Net Debt / EBITDA Ratio | -0.87 | -1.05 | -0.43 | -0.27 | 0.29 | -0.22 |
Net Debt / FCF Ratio | - | -2.04 | -1.80 | -0.54 | -0.56 | -0.42 |
Asset Turnover | - | 0.66 | 0.64 | 0.65 | 0.66 | 0.68 |
Inventory Turnover | - | 3.24 | 3.53 | 3.62 | 3.64 | 3.62 |
Quick Ratio | - | 3.04 | 3.42 | 3.55 | 2.38 | 2.32 |
Current Ratio | - | 4.02 | 4.79 | 5.15 | 3.61 | 3.33 |
Return on Equity (ROE) | - | 11.60% | 8.62% | 8.50% | 8.70% | 2.76% |
Return on Assets (ROA) | - | 5.87% | 4.86% | 6.56% | 5.44% | 5.79% |
Return on Invested Capital (ROIC) | 10.84% | 8.86% | 7.02% | 9.06% | 8.05% | 5.06% |
Return on Capital Employed (ROCE) | - | 10.40% | 8.70% | 11.80% | 10.20% | 11.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.81% | 5.66% | 6.81% | 6.40% | 9.55% | 1.88% |
FCF Yield | 1.09% | 3.59% | 2.39% | 6.32% | -8.02% | 7.71% |
Dividend Yield | 0.28% | 0.70% | 0.43% | 0.45% | 0.71% | 0.67% |
Payout Ratio | - | 8.24% | 6.40% | 7.15% | 7.67% | 35.41% |
Buyback Yield / Dilution | -1.93% | -1.47% | 0.04% | -0.56% | -0.26% | 0.26% |
Total Shareholder Return | -1.65% | -0.78% | 0.46% | -0.11% | 0.45% | 0.93% |